TapewireFind a company

person · Reporting owner

Ogden Christopher

Disclosed activity across 1 company

Tapewire entity
37157
SEC CIK
0001914523

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CytomX Therapeutics, Inc.CTMX · Entity 5124Chief Financial OfficerJune 15, 2026June 17, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CytomX Therapeutics, Inc.

Report date June 15, 2026 · Filed June 17, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect295,324 Reported balance After 2026-06-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-15 · Sale · Disposed 1,624 · Balance 295,324

F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2: Includes 167,249 RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2: Includes 167,249 RSUs.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 15, 2026 Filed Jun 17, 2026 22:38 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 1,624 $3.05 $4,953.20
Disclosure

SEC source: 0001610717-26-000229 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 295,324

F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · balance_after: Includes 167,249 RSUs.

Read SEC document
March 17, 2026 Filed Mar 19, 2026 22:21 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 19,323 $6.42 $124,111.63
Disclosure

SEC source: 0001610717-26-000122 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 296,948

F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · balance_after: Includes 173,082 RSUs.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 21:23 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantStock Option (Right to Buy) · Derivative 325,000 $0.00 Strike: $6.09 $0.00
Disclosure

SEC source: 0001610717-26-000040 · form4.xml · derivative · entry 2

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,000

Underlying: Common Stock · 325,000 shares

Expires 2036-02-01

F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 21:23 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantCommon Stock 90,000 $0.00 $0.00
Disclosure

SEC source: 0001610717-26-000040 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 316,271

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.

F2 · balance_after: Includes 239,987 RSUs.

Read SEC document
September 26, 2025 Filed Sep 30, 2025 22:38 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantPerformance Stock Units (PSUs) · Derivative 39,150 $0.00 $0.00
Disclosure

SEC source: 0001610717-25-000355 · form4.xml · derivative · entry 2

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,150

Underlying: Common Stock · 39,150 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

F2 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

F2 · derivative.expiration_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
September 26, 2025 Filed Sep 30, 2025 22:38 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantStock Option (Right to Buy) · Derivative 78,250 $0.00 Strike: $2.90 $0.00
Disclosure

SEC source: 0001610717-25-000355 · form4.xml · derivative · entry 1

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,250

Underlying: Common Stock · 78,250 shares

Expires 2035-09-25

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Read SEC document
June 16, 2025 Filed Jun 17, 2025 20:11 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 10,614 $2.69 $28,539.98
Disclosure

SEC source: 0001610717-25-000236 · form4.xml · nonDerivative · entry 3

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,271

F4 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.

F2 · balance_after: Includes 149,987 RSUs.

Read SEC document
June 13, 2025 Filed Jun 17, 2025 20:11 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 Exercise / conversionPerformance Stock Units · Derivative 37,500 $0.00 $0.00
Disclosure

SEC source: 0001610717-25-000236 · form4.xml · derivative · entry 4

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each PSU represented a contingent right to receive one (1) share of common stock upon vesting.

F5 · derivative.exercise_date: Each PSU represented a contingent right to receive one (1) share of common stock upon vesting.

F5 · derivative.expiration_date: Each PSU represented a contingent right to receive one (1) share of common stock upon vesting.

Read SEC document
June 13, 2025 Filed Jun 17, 2025 20:11 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 Exercise / conversionCommon Stock 37,500 $0.00 $0.00
Disclosure

SEC source: 0001610717-25-000236 · form4.xml · nonDerivative · entry 2

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 236,885

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023.

F2 · balance_after: Includes 149,987 RSUs.

Read SEC document
June 13, 2025 Filed Jun 17, 2025 20:11 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 1,641 $2.95 $4,841.44
Disclosure

SEC source: 0001610717-25-000236 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,385

F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · balance_after: Includes 149,987 RSUs.

Read SEC document
March 18, 2025 Filed Mar 20, 2025 20:33 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 8,551 $0.60 $5,122.05
Disclosure

SEC source: 0001610717-25-000085 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,026

F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · balance_after: Includes 155,821 RSUs.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 22:55 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantStock Option (Right to Buy) · Derivative 115,000 $0.00 Strike: $0.86 $0.00
Disclosure

SEC source: 0001610717-25-000017 · form4.xml · derivative · entry 4

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 115,000 shares

Expires 2035-02-03

F5 · derivative.exercise_date: 1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 22:55 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantStock Option (Right to Buy) · Derivative 225,000 $0.00 Strike: $0.86 $0.00
Disclosure

SEC source: 0001610717-25-000017 · form4.xml · derivative · entry 3

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2035-02-03

F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 22:55 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantCommon Stock 57,500 $0.00 $0.00
Disclosure

SEC source: 0001610717-25-000017 · form4.xml · nonDerivative · entry 2

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,577

F2 · shares: Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date.

F3 · balance_after: Includes 179,310 RSUs.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 22:55 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantCommon Stock 44,000 $0.00 $0.00
Disclosure

SEC source: 0001610717-25-000017 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,077

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
August 20, 2024 Filed Aug 22, 2024 21:59 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 Exercise / conversionPerformance Stock Units (PSUs) · Derivative 6,875 $0.00 $0.00
Disclosure

SEC source: 0001610717-24-000433 · form4.xml · derivative · entry 3

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone.

F1 · kind: Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.

F4 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone.

F4 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone.

Read SEC document
August 20, 2024 Filed Aug 22, 2024 21:59 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 1,984 $1.23 $2,438.53
Disclosure

SEC source: 0001610717-24-000433 · form4.xml · nonDerivative · entry 2

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,077

F3 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein.

F2 · balance_after: Includes 77,810 restricted stock units.

Read SEC document
August 20, 2024 Filed Aug 22, 2024 21:59 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 Exercise / conversionCommon Stock 6,875 $0.00 $0.00
Disclosure

SEC source: 0001610717-24-000433 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,061

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.

F2 · balance_after: Includes 77,810 restricted stock units.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 20:24 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $1.49 $0.00
Disclosure

SEC source: 0001610717-24-000339 · form4.xml · derivative · entry 2

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2034-06-11

F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from June 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Read SEC document
June 12, 2024 Filed Jun 14, 2024 20:24 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantCommon Stock 17,500 $0.00 $0.00
Disclosure

SEC source: 0001610717-24-000339 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,186

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on June 12 of each year, with the first 1/3rd vesting on June 12, 2025, subject to the Reporting Person continuing as a service provider through each such date.

F2 · balance_after: Includes 77,810 RSUs.

Read SEC document
March 19, 2024 Filed Mar 21, 2024 20:38 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 2,971 $2.09 $6,196.02
Disclosure

SEC source: 0001610717-24-000177 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,686

F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units.

F2 · balance_after: Includes 60,310 restricted stock units.

Read SEC document
January 18, 2024 Filed Jan 20, 2024 01:41 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantPerformance Stock Units (PSUs) · Derivative 75,000 $0.00 $0.00
Disclosure

SEC source: 0001610717-24-000034 · form4.xml · derivative · entry 3

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

F4 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

F4 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
January 18, 2024 Filed Jan 20, 2024 01:41 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantStock Option (Right to Buy) · Derivative 154,000 $0.00 Strike: $1.68 $0.00
Disclosure

SEC source: 0001610717-24-000034 · form4.xml · derivative · entry 2

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,000

Underlying: Common Stock · 154,000 shares

Expires 2034-01-17

F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Read SEC document
January 18, 2024 Filed Jan 20, 2024 01:41 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantCommon Stock 40,000 $0.00 $0.00
Disclosure

SEC source: 0001610717-24-000034 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,657

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date.

F2 · balance_after: Includes 70,466 RSUs.

Read SEC document
December 20, 2023 Filed Dec 22, 2023 21:10 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 1,990 $1.38 $2,747.39
Disclosure

SEC source: 0001610717-23-000419 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,657

F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023.

F2 · balance_after: Includes 30,466 restricted stock units.

Read SEC document
December 17, 2023 Filed Dec 20, 2023 00:58 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 Exercise / conversionPerformance Stock Units (PSUs) · Derivative 6,875 $0.00 $0.00
Disclosure

SEC source: 0001610717-23-000412 · form4.xml · derivative · entry 2

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,875

Underlying: Common Stock · 6,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.

F1 · kind: Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.

F4 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.

F4 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.

Read SEC document
December 17, 2023 Filed Dec 20, 2023 00:58 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 Exercise / conversionCommon Stock 6,875 $0.00 $0.00
Disclosure

SEC source: 0001610717-23-000412 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,647

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.

F2 · balance_after: Includes 30,466 restricted stock units.

F3 · balance_after: Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2023.

Read SEC document
March 16, 2023 Filed Mar 20, 2023 22:43 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 SaleCommon Stock 516 $1.98 $1,021.32
Disclosure

SEC source: 0001140361-23-012619 · form4.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,772

F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units.

F2 · balance_after: Includes 30,466 restricted stock units.

Read SEC document
February 02, 2023 Filed Feb 6, 2023 21:47 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantPerformance Stock Units (PSUs) · Derivative 75,000 $0.00 $0.00
Disclosure

SEC source: 0001567619-23-001927 · doc1.xml · derivative · entry 3

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

F5 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

F5 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
February 02, 2023 Filed Feb 6, 2023 21:47 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $2.59 $0.00
Disclosure

SEC source: 0001567619-23-001927 · doc1.xml · derivative · entry 2

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2033-02-01

F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Read SEC document
February 02, 2023 Filed Feb 6, 2023 21:47 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantCommon Stock 25,000 $0.00 $0.00
Disclosure

SEC source: 0001567619-23-001927 · doc1.xml · nonDerivative · entry 1

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,288

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date.

F2 · balance_after: Includes 32,288 RSUs.

F3 · balance_after: Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2022.

Read SEC document
August 10, 2022 Filed Aug 12, 2022 20:59 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantPerformance Stock Units (PSUs) · Derivative 13,750 $0.00 $0.00
Disclosure

SEC source: 0001567619-22-015864 · doc1.xml · derivative · entry 2

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.

F2 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.

F2 · derivative.expiration_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.

Read SEC document
August 10, 2022 Filed Aug 12, 2022 20:59 UTC CytomX Therapeutics, Inc. CTMX · Entity 5124 GrantStock Option (Right to Buy) · Derivative 82,500 $0.00 Strike: $1.59 $0.00
Disclosure

SEC source: 0001567619-22-015864 · doc1.xml · derivative · entry 1

Ogden Christopher · CIK 0001914523 · SVP, Finance and Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,500

Underlying: Common Stock · 82,500 shares

Expires 2032-08-09

F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.